14741-71-0

Basic information

• Product Name: (1H-BENZOIMIDAZOL-2-YL)-ACETIC ACID ETHYL ESTER
• Synonyms: 2-(1H-benzimidazol-2-yl)acetic acid ethyl ester;ethyl 2-(1H-benzimidazol-2-yl)acetate;ethyl 2-(1H-benzimidazol-2-yl)ethanoate;Ethyl 2-(1H-1,3-benzimidazol-2-yl)acetate;ethyl 1H-benzimidazol-2-ylacetate;ethyl 2-(1H-benzo[d]iMidazol-2-yl)acetate;1H-Benzimidazole-2-acetic acid, ethyl ester 97%
• CAS NO: 14741-71-0
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 204.22
• Mol File: 14741-71-0.mol
• Article Data: 20

Chemical Properties

• Melting Point: 128.5-129.5 °C
• Boiling Point: 408.3°Cat760mmHg
• Flash Point: 200.7°C
• Appearance: /
• Density: 1.242g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.47±0.10(Predicted)
• CAS DataBase Reference: (1H-BENZOIMIDAZOL-2-YL)-ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (1H-BENZOIMIDAZOL-2-YL)-ACETIC ACID ETHYL ESTER(14741-71-0)
• EPA Substance Registry System: (1H-BENZOIMIDAZOL-2-YL)-ACETIC ACID ETHYL ESTER(14741-71-0)

Safety Data

• Hazardous Substances Data: 14741-71-0(Hazardous Substances Data)

Usage

General Description

(1H-benzoimidazol-2-yl)-acetic acid ethyl ester, also known as ethyl 1-(1H-benzo[d]imidazol-2-yl)acetate, is a chemical compound with the molecular formula C11H12N2O2. It is an ester derivative of (1H-benzoimidazol-2-yl)acetic acid, and is commonly used in the pharmaceutical industry as a building block for the synthesis of various bioactive compounds. This chemical possesses a wide range of pharmacological properties, including antiviral, anti-inflammatory, and anticancer activities. The synthesis and study of this compound have shown promising results for potential therapeutic applications, making it an important intermediate in the development of new pharmaceutical products.

InChI:InChI=1/C11H12N2O2/c1-2-15-11(14)7-10-12-8-5-3-4-6-9(8)13-10/h3-6H,2,7H2,1H3,(H,12,13)

Upstream product

• 4981-92-4 1-benzylbenzimidazole 
• 51-17-2 benzoimidazole 
• 7711-28-6 (1-benzyl-1H-benzoimidazol-2-yl)-acetic acid ethyl ester 
• 95-54-5 1,2-diamino-benzene 
• 105-53-3 diethyl malonate 
• 4414-88-4 1H-benzimidazol-2-acetonitrile 
• 13570-08-6 (1H-benzimidazol-2-yl)acetic acid 
• 64-17-5 ethanol 
• 27317-59-5 Ethyl 3-ethoxy-3-iminopropionate 
• 105-56-6 ethyl 2-cyanoacetate 
• 2318-25-4 ethyl 3-ethoxy-3-iminopropanoate hydrochloride 
• 105-58-8 Diethyl carbonate 

Downstream Products

• 1354647-68-9 ethyl 2-(1H-benzimidazol-2-yl)-3-(2-chlorophenyl)prop-2-enoate 
• 332897-64-0 ethyl 1,3-dimethylbenzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate 

Relevant articles and documents

Synthesis and antibacterial activity of novel ethyl 2-alkoxyimino-2-benzimidazol-2-yl acetates bearing a morpholine group

In the search for new benzimidazole derivatives with high antibacterial activity and for which bacterial resistance is low, novel ethyl 2-(alkoxyimino)-2-[1-(4-morpholinocarbonylmethyl)-1H-benzimidazol-2-yl]acetates have been synthesized by multi-step rea

Composition based on benzimidazole carboxylic acid compound and application thereof

The invention belongs to the field of medicine and pharmacology, and particularly relates to a pharmaceutical composition taking benzimidazole carboxylic acid and pharmaceutically acceptable salt thereof as active ingredients. The pharmaceutical composition taking the benzimidazole carboxylic acid and pharmaceutically acceptable salt thereof as main active ingredients is used for preventing and/ortreating respiratory tract reaction and nasal congestion caused by allergic reaction, nasal congestion caused by other reasons and other symptoms, and can realize immediate and/or lasting alleviationof congestion. The invention also provides a method of treating and/or alleviating and/or preventing nasal congestion in a patient, the method comprising administering to a patient in need thereof aneffective amount of the pharmaceutical composition of the benzimidazole carboxylic acid or a pharmaceutically acceptable salt thereof.

Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors

The synthesis of benzimidazole linked oxadiazole derivatives designed as potential EGFR and erbB2 receptor inhibitors with anticancer and apoptotic activity were studied. Compounds 7a specifically inhibit EGFR and erbB2 receptor at 0.081 and 0.098 μM concentration. Some of the compounds showed strong, broad-spectrum antiproliferative activitiy when tested against five human cancer cell lines. Compounds 7a and 7n were more cytotoxic than 5-fluorouracil against MCF-7 cancer cell, with IC50values of 5.0 and 2.55 μM whereas, only 7a led to cell cycle arrest at G2/M phase accompanied by an increase in apoptosis. Compounds 7a and 7n showed normal architecture of myofibrils in cardiomyopathy study whereas only compound 7a showed nearly equal biochemical parameters (SGOT and SGPT) when compared to control. Molecular docking & 3D-QSAR studies were used to establish interactions of 7a and 7n within the active site of enzyme for ATP binding site of kinase domain.